Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I
533 AN INHIBITOR OF THE FUMARYLACETOACETATE HYDROLASE (FAH) TO SELECT FOR GENE CORRECTED HEPATOCYTES IN VIVO
Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries
Fumarylacetoacetate Hydrolase
